Calcitonin is a 32-amino-acid peptide hormone produced by the parafollicular (C) cells of the thyroid. It lowers serum calcium by inhibiting osteoclastic bone resorption, and it was one of the first peptide hormones to be developed as a medicine. Its history is a useful case study in how an established peptide can lose an indication when the risk-benefit balance shifts.
This explainer covers three things: what calcitonin does and how it has been used, the receptor family it shares with amylin and CGRP, and the UK and European regulatory position. It is written for research and educational purposes only; no compound described here is presented for human use outside a marketing authorisation or a clinical trial.
What calcitonin is and how it works
Calcitonin is secreted by thyroid C cells in response to rising plasma calcium. Its principal action is to inhibit osteoclast activity, reducing bone resorption and lowering serum calcium. In pharmacological form it has been used for disorders of bone metabolism: Paget's disease of bone, acute bone loss from sudden immobilisation, hypercalcaemia of malignancy, and, historically, postmenopausal osteoporosis.
The therapeutic form is salmon calcitonin - a synthetic peptide that differs from human calcitonin in sequence and is more potent and longer-acting in humans. It was developed as both an injectable solution and an intranasal spray.
The calcitonin receptor family
Calcitonin is the founding member of a small family of structurally related peptides. Its receptor, CALCR (the calcitonin receptor), is a class B G-protein-coupled receptor whose pharmacology depends on which receptor-activity-modifying protein (RAMP) it associates with:
- CALCR with RAMP1 forms the AMY1 receptor
- CALCR with RAMP2 forms the AMY2 receptor
- CALCR with RAMP3 forms the AMY3 receptor
Amylin (islet amyloid polypeptide, IAPP), CGRP and adrenomedullin signal through related CALCR/RAMP or CLR/RAMP complexes. That shared architecture is why amylin analogues and calcitonin sit in the same pharmacological neighbourhood, and why AMY-receptor selectivity is a live question in the design of next-generation amylin agonists.
The UK and European regulatory position
Calcitonin is not widely used in the UK. In 2012 the MHRA issued a Drug Safety Update reporting that a Europe-wide review had found malignancies more frequently in patients treated with calcitonin than with placebo, with an absolute increased risk of between 0.7% and 2.4%. The review concluded that the benefits of calcitonin no longer outweighed its risks in the treatment of osteoporosis.
On that basis the European Committee for Medicinal Products for Human Use (CHMP) recommended that the intranasal formulation - licensed only for osteoporosis - be withdrawn from the European market. Injectable calcitonin was retained for short-term treatment of Paget's disease, acute bone loss due to sudden immobilisation, and hypercalcaemia of malignancy. Healthcare professionals were advised to stop prescribing calcitonin for osteoporosis and to review patients on intranasal calcitonin.
Anyone checking the position today should confirm the status of a specific product against the MHRA product register and the electronic medicines compendium rather than assume that an older authorisation remains in force. A peptide's presence in a historical formulary is not evidence that it is currently licensed.
What the evidence does and does not show
Calcitonin has a long published record, but the evidence that decided its regulatory fate was the long-term safety signal, not efficacy. The osteoporosis indication was withdrawn because the cancer risk, though small in absolute terms, was judged to outweigh the benefit in a condition for which safer alternatives exist. The surviving injectable indications are short-term and narrow.
That is the honest summary: calcitonin is a well-characterised peptide hormone whose clinical use has narrowed sharply for safety reasons. It should not be described as a treatment for any condition, and it is not a research peptide for self-directed use.
Bottom line
- Calcitonin is a 32-amino-acid peptide hormone that inhibits bone resorption.
- It shares the CALCR receptor - and, via RAMP proteins, the AMY1-3 receptor subtypes - with amylin, CGRP and adrenomedullin.
- Intranasal calcitonin was withdrawn from the European market in 2012 after a long-term cancer signal; injectable calcitonin remains for short-term use in narrow indications.
- Calcitonin is not widely used in the UK, and its licensing position should be checked product by product.
Research use only. Nothing in this article is medical advice, and nothing here should be read as guidance on the use of any compound in humans.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.